FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:486-487 February 11, 1999 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

By Robert Bazell. 214 pp. New York, Random House, 1998. $23.95. ISBN 0-679-45702-X.

This book describes the development of a new type of therapy for breast cancer, from the discovery of the molecular target to the completion of successful randomized, clinical trials and approval for use.

It is written as the story of the triumph of an inspired clinician against great opposition, which included his own colleagues, grant-awarding agencies, and pharmaceutical companies. There is no doubt that Dennis Slamon discovered the role of the erbB2 (her2) oncogene in breast and ovarian cancer and played a major part in preclinical studies that showed that inhibition of this molecular target was worthwhile. He . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.